alexa Biological Basis For Rational Use Of Erythropoietin Stimulating Agents | 17566
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Nephrology & Therapeutics
June 26-27, 2014 Valencia Conference Centre, Valencia, Spain

Mark S Segal
Accepted Abstracts: J Nephrol Ther
DOI: 10.4172/2161-0959.S1.016
Abstract
E rythropoietin stimulating agents have been instrumental in improving the lives of patients on dialysis, decreasing transfusions, and reducing sensitization. However over the past 10 years, there have been a number of large clinical trials such as TREAT, CHOIR, and the Normal Hematocrit Study demonstrating that targeting a higher hematocrit leads to worse outcomes. In addition, trials have demonstrated that higher doses of erythropoietin lead to a higher recurrence of cancers. What has been lacking is a biologic basis for these untoward results. There are two known receptors for erythropoietin, the homodimeric erythropoietin receptor, responsible for erythropoiesis, and the more ubiquitous heterodimeric erythropoietin receptor consisting of an erythropoietin receptor and the beta-common receptor. These receptors have different Km?s with the Km of the heterodimeric erythropoietin receptor/beta-common receptor being ten-fold higher than the homodimeric erythropoietin receptor. Thus, targeting a higher hemoglobin with larger doses of erythropoietin stimulating agent increases the likelihood of stimulation of the heterodimeric erythropoietin receptor/beta-common receptor. Our work has demonstrated that stimulating the heterodimeric erythropoietin receptor/beta-common receptor can explain all of the untoward events seen in the clinical trials. Thus understand the biology of both erythropoietin receptors leads to a rational set of guidelines for use of erythropoietin stimulating agents and a rational set of guidelines to predict the safety profile of the novel agents to stimulate erythropoiesis
Biography
Mark S Segal did his undergraduate work at MIT and was than recruited to the MD/PhD program at The University of Texas Southwestern Medical Center at Dallas. He did his internship and residency at The University of Texas Southwestern Medical Center at Dallas, and did his Nephrology fellowship training at Beth Israel Deaconess Medical Center. He was then recruited to University of Florida in 1999 and was appointed Chief of the Division of Nephrology in 2010. He is well funded for his research on markers of vascular health and has presented his research at national and international meetings
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version